IL-1β antibodies alleviate memory and cognitive impairments in 3xTg-AD mice by inhibiting nuclear factor κB (NF-κB) activation and reducing the activation of tau-related kinases, including the cyclin-dependent kinase 5/p25 (cdk5/p25), glycogen synthase kinase-3β (GSK-3β), and P38 mitogen-activated protein kinase (p38-MAPK) (Feng et al., 2020). The gene discussed is CDK5; the disease is Alzheimer disease.